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Abstract
Background: Numerous studies have demonstrated associations between genetic markers and COPD, but results
have been inconsistent. One reason may be heterogeneity in disease definition. Unsupervised learning approaches
may assist in understanding disease heterogeneity.
Methods: We selected 31 phenotypic variables and 12 SNPs from five candidate genes in 308 subjects in the
National Emphysema Treatment Trial (NETT) Genetics Ancillary Study cohort. We used factor analysis to select a
subset of phenotypic variables, and then used cluster analysis to identify subtypes of severe emphysema. We
examined the phenotypic and genotypic characteristics of each cluster.
Results: We identified six factors accounting for 75% of the shared variability among our initial phenotypic
variables. We selected four phenotypic variables from these factors for cluster analysis: 1) post-bronchodilator FEV1
percent predicted, 2) percent bronchodilator responsiveness, and quantitative CT measurements of 3) apical
emphysema and 4) airway wall thickness. K-means cluster analysis revealed four clusters, though separation
between clusters was modest: 1) emphysema predominant, 2) bronchodilator responsive, with higher FEV1;3 )
discordant, with a lower FEV1 despite less severe emphysema and lower airway wall thickness, and 4) airway
predominant. Of the genotypes examined, membership in cluster 1 (emphysema-predominant) was associated
with TGFB1 SNP rs1800470.
Conclusions: Cluster analysis may identify meaningful disease subtypes and/or groups of related phenotypic
variables even in a highly selected group of severe emphysema subjects, and may be useful for genetic association
studies.
Background
C h r o n i cO b s t r u c t i v eP u l m o n a r yD i s e a s e( C O P D )i s
defined by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) as airflow limitation that is not
fully reversible[1]. This deliberately broad and simple
definition based on reduced expiratory airflow has been
useful in leading to increased awareness and under-
standing of the disease[2]. However, substantial hetero-
geneity within this definition exists[3,4]. Moving beyond
spirometry and evaluating other variables is critical to
understanding differences in patients with COPD, to
gain mechanistic insights into the disease, to identify
those at highest risk of specific outcomes, and to perso-
nalize therapy [4-7].
Substantial evidence indicates that genetic variation
contributes to differences in COPD susceptibility; how-
ever, replication of genetic associations in COPD - and
in many other complex diseases - has generally been
poor[8]. Disease heterogeneity is likely an important fac-
tor for these inconsistent findings[9,10]. Several
attempts to overcome heterogeneity have been used,
including using classic subtypes of chronic bronchitis or
emphysema[11], defining subtypes based on a pathophy-
siologic characteristic (such as rapid or slow decline in
lung function[12]), or assessing phenotypic characteris-
tics by chest CT scans[13]. * Correspondence: remhc@channing.harvard.edu
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extract novel patterns and trends from phenotypic data
[14], and thus identify COPD subtypes without using a
priori expectations about disease characteristics[15-20].
To our knowledge, these strategies have not been
applied in a group with severe emphysema, nor have
studies used these subtypes in a genetic association
study. We hypothesized that cluster analysis would iden-
tify distinct subtypes of COPD subjects, and that var-
iants in COPD candidate genes would be associated
with these subtypes.
Methods
Details of subject recruitment and phenotyping in the
National Emphysema Treatment Trial (NETT) have
been reported previously[21]. Briefly, NETT participants
had physician-diagnosed COPD, FEV1 ≤ 45% predicted,
evidence of hyperinflation on pulmonary function test-
ing, and bilateral emphysema on chest CT scan. Enroll-
ment in the NETT Genetics Ancillary Study began after
the initiation of the clinical trial, and thus only a subset
of the original cohort had DNA available for genotyping.
The characteristics of NETT subjects included and
excluded from this analysis are shown in Additional File
1, Table S1. Participants gave written informed consent.
The appropriate institutional review boards approved all
studies. Self-identified white subjects in the NETT
Genetics Ancillary Study with complete CT phenotypic
data (emphysema and airway wall quantitative measures)
were included in the analysis.
We selected a set of 31 CT, lung function, and other
key phenotypic variables, based on clinical relevance,
i n c l u s i o ni np r e v i o u sg e n e t i ca s s o c i a t i o ns t u d i e s ,a n d
complete data, to avoid subject drop-out (Table 1). Mea-
surements of the phenotypic variables have been pre-
viously described[21-25]. 12 SNPs from 5 genes were
chosen on the basis of available genotyping and prior
associations with COPD (Table 2), and included genes
involved in xenobiotic metabolism (EPHX1 and GSTP1)
and surfactant homeostasis (SFTPB), as well as two
genes identified in part through linkage studies: TGFB1,
a cytokine growth factor, and SERPINE2,at h r o m b i n
and urokinase inhibitor. A limited number of SNPs
were selected in order to limit multiple statistical testing
in this relatively small study population[26]. For the
gene SERPINE2[27,28], in which numerous associations
have been described, we chose SNPs tagging associa-
tions found in at least two populations, using a r
2 cutoff
of > 0.8 in Tagger [29] as implemented in Haploview
4.1 [30].
We used factor analysis as a guide to determine which
COPD phenotypic variables to include in our clustering
analysis[31]. Factor analysis is a data reduction techni-
que related to principal component analysis, where
shared variability in several observed variables is
explained in terms of fewer unobserved variables, called
factors. The strength of the relationship between the
observed variables and factors can be measured by fac-
tor loadings. We used factor analysis in two ways: first,
to select variables which represent greater amounts of
shared variability; and second, among these variables, to
select one representative measurement using a high fac-
tor loading to avoid over-weighting correlated COPD
characteristics, which could bias a cluster analysis.
The goal of cluster analysis is to assign subjects to
groups, where subjects in the same cluster are more
similar to each other than they are to subjects in other
groups[14]. Similarity is generally defined using a mea-
surement of distance, calculated using the difference
between measurements. As numerous clustering meth-
ods exist, we evaluated the performance of several clus-
tering algorithms. We chose the best performing
clustering technique and clu s t e rn u m b e ru s i n gt h es i l -
houette width, a measure of how close each point in
one cluster is to points in neighboring clusters. We then
examined each variable for differences among the
clusters.
Results
A total of 308 subjects from the NETT Genetics Ancillary
Study were included in the analysis. Phenotypic variables
selected for inclusion in the factor analysis are shown in
Table 1. SNPs included for analysis, along with their
minor allele frequencies and previous genetic association
studies in COPD (both in the NETT cohort and others)
are listed in Table 2. Six factors accounted for 75% of the
common variance. Eigenvalues for these factors ranged
from 1.7 to 4.9; two additional factors (not shown) had
eigenvalues > 1.0. The results of the factor analysis are
shown in Table 1. These factors were interpreted as: 1)
spirometry (containing pre- and post-bronchodilator FEV1
and FVC percent predicted); 2) airway wall thickness (wall
thickness, derived square root wall area of a 10 mm inter-
nal perimeter airway and derived wall area percent of
a1 0m ma i r w a y ) ;3 )F E V 1/FVC ratio; 4) quantitative
emphysema severity and distribution (divided into equal
thirds by absolute lung height from apex to base), using a
cutoff of -950 Hounsfield units; 5) bronchodilator respon-
siveness; and 6) maximum work and gender. The follow-
ing variables were chosen as representative based on
relatively high factor loadings, accounting for a greater
proportion of shared variability: post-bronchodilator FEV1
percent predicted (for factors 1 and 3), airway wall thick-
ness (factor 2), apical emphysema (factor 4), and broncho-
dilator responsiveness (factor 5).
Based on measures of silhouette width, the k-means
clustering algorithm using four clusters was found to be
optimal for this dataset. This optimal value was low
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A plot of the clusters with each pair of phenotypic vari-
ables is shown in Additional file 1, Figure S1. Differ-
ences between the selected phenotypic variables by
cluster are shown in Table 3. As expected, all selected
phenotypic variables selected for use in cluster analysis
were significantly different between clusters (P < 10
-3).
Cluster 1 had the greatest degree of emphysema and the
least airway wall thickness, as well as a lower FEV1.
Conversely, cluster 4 had the highest airway wall thick-
ness and the least emphysema, and also had lower
bronchodilator responsiveness and FEV1. Cluster 2 was
a milder subgroup, with the highest FEV1 and broncho-
dilator responsiveness, as well as less emphysema.
Cluster 3 also had less emphysema and in addition, less
airway wall thickness; however, in contrast to cluster 2,
this cluster was more severely affected with the lowest
FEV1 and bronchodilator responsiveness.
Additional phenotypic variables, not included in the
cluster analysis, were then examined to determine other
characteristics of these clusters. Significant differences
among the groups were found for several characteristics
(Table 3). Cluster 1, the emphysema predominant cluster,
had a lower BMI, fewer pack-years of smoking, higher
total lung capacity, and lower diffusing capacity, along
w i t hal o w e rs i xm i n u t ew a l kd i s t a n c ea n dm a x i m u m
work. Consistent with the radiographic clustering and the
factor loadings, CT emphysema severity and apical-basal
Table 1 Factor analysis.
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6
Age, years 0.226
BMI, kg/m2 0.272 -0.123 0.117
Gender (% male) 0.181 -0.119 0.153 -0.712
Pack-years of smoking 0.187
Age started smoking -0.237
Age quit smoking 0.146 0.14 -0.11
Pre-bronchodilator FEV1, % predicted 0.852 0.466 -0.181 0.1
Pre-bronchodilator FVC, % predicted 0.903 -0.247 0.154
Post-bronchodilator FEV1, % predicted 0.853 0.461 0.209
Post-bronchodilator FVC, % predicted 0.899 -0.301 0.172 0.193
Bronchodilator response, % of baseline FEV1 0.979
Bronchodilator response, absolute change in FEV1, L 0.163 0.943 0.183
FEV1/FVC ratio, post-bronchodilator 0.104 0.961 -0.134
FEV1/FVC ratio, pre-bronchodilator 0.902 -0.106
Total lung capacity, % predicted -0.165 -0.227 0.151
Residual volume, % predicted -0.506 -0.145 0.199 -0.132
Diffusion capacity, % predicted 0.169 0.219 -0.253 0.286
Total fraction emphysema at -950 HU -0.214 -0.178 0.822
Difference between apical and basal emphysema at -950 HU 0.846 -0.108
Apical fraction emphysema at -950 HU -0.141 0.981
Airway wall thickness, mm 0.96
Airway wall area, % 0.94 -0.114
Square root wall area, cm 0.882
6 minute walk distance, ft 0.175 -0.105 0.104 0.566
Maximum work, watts 0.174 0.135 -0.1 0.164 0.791
UCSD Shortness of Breath Questionnaire -0.227 -0.307
Arterial pH 0.212 0.107 0.146
PaO2, mmHg 0.2 0.205 0.256
PaCO2, mmHg -0.293 -0.345 -0.104 -0.166
Exacerbations in year prior to randomization -0.123 -0.113
Exacerbations/year (over 3.3 years) -0.107 -0.204 0.152
Six factors were identified accounting for 75% of the common variance. Higher factor loadings indicate higher correlations of the variable with that factor.
Loadings ≥ |0.1| are shown.
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emphysema in the upper lung region minus the lower
lung region) were more severe, while airway wall area and
square root of wall area were lower. Conversely, cluster 4,
the airway predominant cluster, had a higher BMI, lower
total lung capacity, and less severe emphysema and higher
airway wall measurements, with a lower PaO2 and lower
six minute walk distance. Cluster 2, the milder severity,
bronchodilator responsive subtype, had a higher BMI,
greater FVC and DLCO, a lower PaCO2, higher six minute
walk distance and maximum work, fewer symptoms of
dyspnea, and fewer exacerbations, despite being of slightly
older age. Cluster 3, with a lower FEV1 despite less severe
radiographic emphysema and airway wall thickness than
the other clusters, had more dyspnea and a higher PaCO2,
with slightly younger age.
To determine whether specific SNPs were associated
with cluster membership, we tested genotypes for each
of the 12 candidate gene SNPs with cluster membership.
A chi-squared P value of 0.034 was seen for a SNP in
TGFB1, rs1800470; no other P values were nominally
(<0.05) significant. In pairwise testing using an additive
model of each cluster versus all other clusters, this
SNP was associated with membership in cluster 1
(P = 0.002).
Further details on study methods and additional
results are available in Additional File 1, including plots
of correlations and cluster separation in two-dimen-
sional space (Additional file 1, Figures S1 and S3).
Discussion
Despite the description of COPD subtypes more than 40
years ago[32] and substantial progress since then in
understanding COPD-related phenotypes[33,34], only a
few attempts have been made to use statistical methods
to define novel COPD subtypes[15,16]. Using a large,
well-characterized set of subjects with severe emphy-
sema, we demonstrate the potential utility of using sta-
tistical learning methods to find relationships among
phenotypic and genotypic characteristics to elucidate
disease heterogeneity.
Several methods have attempted to address issues of
disease heterogeneity in obstructive airway diseases. Sta-
tistical learning techniques such as factor analysis have
been used to reveal novel insights into characteristics
such as dyspnea or inflammation in COPD[20,35-37].
Cluster analysis has confirmed classic chronic bronchitis
and emphysema subtypes[15] or illustrated overlap of
characteristics of COPD and asthma[16], and a combi-
nation of factor analysis and cluster analysis has defined
Table 2 Single nucleotide polymorphisms (SNPs).
Gene
Symbol
SNP Major/
Minor
Allele
Minor
Allele
Frequency
Association in NETT (Effect of Variant Genotype) Other Reported COPD Association(s)
EPHX1 rs1051740
(Tyr113His)
T/C 0.31 Less maximum work[42] Associations with discordant directions;
meta-analysis with a protective effect of
the variant allele[55]
rs2234922
(His139Arg)
A/G 0.19 Decreased risk of COPD [9]; Lesser degree of apical
minus basilar emphysema [22]; increased DLCO[42], less
maximum work after LVRS[56]
Wild type with variant type rs1051740,
associated with lung function decline
[12]
GSTP1 rs1695 (aka
rs947894)
A/G 0.36 Lesser degree of apical and apical minus basilar
emphysema [22]
Associations with discordant directions
[57]
SERPINE2 rs6734100 C/G 0.15 Case-control and family-based; variant
less common in cases[28]
rs6747096 A/G 0.19 Protection from COPD [27]
rs975278 C/T 0.20 Decreased apical emphysema [22] Decreased risk of COPD [28]
SFTPB rs1130866
(Thr131Ile)
A/G 0.46 Associated with COPD, in the presence of a gene-by-
environment interaction[9]; fewer exacerbations[23]
Associated with COPD [9,58]
rs2118177 T/C 0.35 Fewer exacerbations[23]
rs2304566 T/C 0.25 Fewer exacerbations[23]
rs3024791 C/T 0.16 Fewer exacerbations[23]
TGFB1 rs1800470 (aka
rs1982073)
(Leu10Pro)
A/G 0.39 Decreased risk of COPD [59]; lower FEV1 within
emphysema subjects[48]; increased apical emphysema
[22]; decreased airway wall thickness (unpublished
observations)
Decreased risk of COPD[60,61]
rs1800469 G/A 0.30 Decreased risk of COPD[59]; lower FEV1 within
emphysema subjects[48]; greater dyspnea symptoms
[42]; increased apical emphysema[22]
Twelve SNPs from nine candidate genes were chosen based on available genotyping and previous associations.
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Cohort Groupwise Test Cluster
123 4
N 308 66 102 88 52
Phenotypic Variables
Post-bronchodilator FEV1, % predicted 28.3 (7.33) 2.60 × 10
-28 26.5* 34.3** 23.9** 26.2*
Bronchodilator response, % of baseline FEV1 13.6 (0.12) 5.10 × 10
-19 13.4 21.5** 6.6** 10.5*
Apical fraction emphysema at -950 HU
† 0.21 (0-0.72) 9.60 × 10
-30 0.47** 0.17** 0.16** 0.15*
Airway wall thickness, mm 1.53 (0.25) 5.10 × 10
-54 1.36** 1.50 1.45** 1.93**
Age (years) 67.4 (6.08) 0.023 66.5 68.6* 66.3* 68.2
BMI (kg/m
2) 25.1 (3.45) 0.0001 23.7** 25.7* 24.7 26.1*
Gender (% male) 64 0.37 56 64 69 67
Pack-years of smoking 67.4 (30.4) 0.13 60.08** 68.57 68.47 72.73
Age started smoking 16.4 (3.58) 0.37 16.74 16.60 15.85 16.63
Age quit smoking 57.7 (7.58) 0.12 56.72 58.89 56.68 58.61
Pre-bronchodilator FEV1 % predicted 25.0 (6.55) 5.80 × 10
-11 23.48* 28.57** 22.6** 23.89
Pre-bronchodilator FVC % predicted 61.3 (15.4) 4.10 × 10
-7 59.0 68.2** 57.3** 57.5
Post-bronchodilator FVC % predicted 69.6 (15.7) 6.70 × 10
-14 67.5 79.1** 62.9** 65.2*
Bronchodilator response, absolute change in FEV1, L 0.09 (0.09) 1.90 × 10
-28 0.08 0.16** 0.04** 0.07**
FEV1/FVC ratio (pre-bronchodilator) 0.32 (0.06) 0.13 0.32 0.33 0.31 0.33
FEV1/FVC ratio (post-bronchodilator) 0.32 (0.06) 2.10 × 10
-5 0.31 0.34** 0.30** 0.31
Total lung capacity, %predicted 128 (15.3) 3.00 × 10
-4 132.7** 126.3 129.4 121.2**
Residual volume, % predicted 216 (47.4) 1.20 × 10
-08 235.3** 195.8** 229.3** 208.9
Diffusion capacity, % predicted 30 (10.1) 4.60 × 10
-6 25.2** 33.1** 29.0 31.7
Total fraction emphysema at -950 HU
† 0.15 (0-0.50) 3.40 × 10
-25 0.31** 0.13** 0.12** 0.11**
Difference between fraction apical and basal emphysema at -950 HU
† 0.12 (-0.33-0.64) 2.80 × 10
-22 0.37** 0.08** 0.06** 0.08
Airway wall area, % 73.3 (3.96) 9.90 × 10
-39 70.4** 73.2 72.4** 78.7**
Square root airway wall area, cm 4.6 (0.50) 2.10 × 10
-32 4.3** 4.6 4.5** 5.3**
6 minute walk distance (ft) 1265 (318) 1.90 × 10
-5 1192.2* 1382.1** 1247.2 1155.7*
Maximum work (watts) 43.8 (22.3) 5.20 × 10
-7 35.5** 53.4** 40.9 40.3
UCSD Shortness of Breath Questionnaire Score 58.9 (17.6) 0.0012 61.4 54.0** 63.5** 57.4
Arterial pH 7.42 (0.03) 0.64 7.43 7.42 7.42 7.42
PaO2, mmHg 64.8 (10.8) 0.048 64.2 67.0* 64.3 62.1*
PaCO2, mmHg 42.5 (5.62) 1.00 × 10
-4 42.0 40.8** 44.3** 43.7
Exacerbations in year prior to randomization
† 0 (0-4) 0.058 0 0** 0 0
Exacerbations/year (over 3.3 years)
† 0.16 (0-3.12) 0.054 0.19 0.00** 0.19 0.15
rs1800470 TGFB1
‡
AA 36% 0.04 24%** 42% 34% 45%
AG 50% 51%** 46% 55% 57%
GG 14% 25%** 12% 12% 8%
Baseline values are for the entire cohort given as mean (sd) unless noted. P values represent tests for groupwise differences between the clusters (see text);
values for the clusters represent mean or medians within the cluster. All 31 phenotypic characteristics used for clustering are shown; those not significant at
P < 0.05 are displayed in italics. Genotype frequencies are given for the nominally significant association between rs1800470 and cluster assignments.
* P < 0.05, ** P < 0.01 in pairwise comparisons of cluster versus remainder of sample.
† Median (range)
‡ Values given as genotype frequency
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identifying disease subtypes (subsets of subjects), or
intermediate disease-related phenotypic characteristics
(endotypes/endophenotypes[38]). Endophenotypes have
already been of substantial utility in genetic association
studies in psychiatry[39].
To date, however, there has been limited use of dis-
ease subtypes in genetic association studies in COPD.
Investigators have tested for specific associations with
classic subtypes[11,40,41], or with specific disease-
related phenotypic characteristics such as emphysema
distribution[22] or functional measures[42]. Factor ana-
lysis has been used to demonstrate differences in herit-
ability of components of asthma[43]. Cluster analysis is
frequently used in gene expression, and such analyses
have been used to define subtypes - though these sub-
types have not always been clearly associated with the
available clinical characteristics[44]. Our study demon-
strates the potential utility of statistical learning meth-
ods in the heterogeneous syndrome of COPD.
Our cluster analyses identified four subtypes of sub-
jects in this cohort with severe emphysema: 1) emphy-
sema predominant, 2) milder severity, bronchodilator-
responsive, 3) discordant lung function/CT emphysema
and airway severity, and 4) airway predominant. Some
of the phenotypic associations in these groups, such as a
lower BMI with more severe quantitative CT emphy-
sema, have been previously seen[13,45], while others,
such as a higher bronchodilator responsiveness in the
group with higher FEV1, differ from previous reports
[46,47]. The association of the nonsynonymous Leu10-
Pro TGFB1 SNP rs1800470 with cluster 1 is consistent
with a previously reported association of apical emphy-
sema in this cohort [22] and association of this SNP
with reduced lung function has also been seen in a Japa-
nese emphysema cohort[48]. Notably, this SNP has been
demonstrated to be of functional significance, with the
G allele (C on the reverse strand) resulting in increased
production of TGFB1[49]. Several studies have demon-
strated an increase in TGFB1 both in the lung[50-52]
and in plasma[53] in subjects with COPD, as well as a
relationship between TGFB1 levels and lung function,
though the relationship between these findings and the
rs1800470 genotype is not entirely clear[53].
Conversely, most of the previously reported SNP asso-
ciations with COPD-related phenotypic characteristics
did not demonstrate associations with our clusters. Non-
significant findings could be due to loss of power from
categorical cluster assignment and resulting small sam-
ple size, and the use of an omnibus test for genetic asso-
ciation. More importantly, our analysis attempts to
determine whether genetic variants lead to a subtype of
COPD subjects which share a set of phenotypic charac-
teristics; as such, it does not attempt to determine the
specific genotypic-phenotypic variables whose relation-
ship leads to a significant association. Whether one of
these approaches - association analysis with individual
phenotypic characteristics, or with subtypes of subjects-
is superior in identifying replicated genetic associations,
or whether the approaches are separately informative,
remains to be seen.
Our study has several strengths. First, we used rela-
tively unbiased methods, in both factor analysis and
cluster analysis, to select uncorrelated variables and
determine severe COPD subtypes using the rich set of
phenotypic and quantitative measures available in
NETT. Second, our analysis is the largest reported clus-
ter analysis using CT phenotypic variables. Third,
despite our homogeneous study population, we were
able to discern emphysema subtypes, which differed on
variables not used to perform clustering. While all four
of these subtypes have not previously been identified,
our emphysema and airway-predominant clusters are
consistent with a priori defined subtypes used in pre-
vious studies[13]. Importantly, recent evidence shows
that airway wall thickening and emphysema aggregate
independently in families of individuals with COPD[54],
suggesting that recognizing these differences may be
important for discovering genetic associations.
Our results should be regarded as exploratory for sev-
eral reasons. First, our dataset was based on available
NETT data. Specific relationships between variables -
for example, the high correlation between apical and
total emphysema - may be due to selection biases of the
NETT population. NETT subjects were likely biased
towards those without predominant airway disease, and
CT scans were suboptimal for assessment of airway wall
remodeling due to the thicker slices associated with pre-
MDCT (multi-detector CT) imaging. Similarly, our gen-
otypic data was limited to a pre-specified subset of pre-
vious positive associations in candidate genes, and our
cohort was limited to those enrolled in the NETT
Genetics Ancillary Study (Additional File 1, Table S1).
Our selection of phenotypic and genotypic variables for
inclusion was strongly influenced by the limitations of
available data, and decisions were made based on clini-
cal judgement of relevance.
Second, our analysis also found that the separation of
clusters was weak, indicating segmentation and not a
true separation of these subtypes using clustering. Cor-
respondingly, we found no strong evidence of smaller
groups of more distinct subtypes. Furthermore, the
small size of our clusters limits the power of association
analysis, and our association with rs1800470 was not
corrected for multiple comparisons. Given these limita-
tions in this relatively homogeneous cohort, an attempt
to validate these findings of specific subtypes using
these or similar methods in other well-phenotyped
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erogeneous and less selected group of subjects, in com-
bination with improved radiographic measures, may
result in more pronounced and distinct subpopulations.
Conclusions
T h ev o l u m eo fg e n e t i ca n dp h e n o t y p i ci n f o r m a t i o n
available in COPD cohorts is rapidly increasing; the
number of potential relationships between phenotypic
and genotypic characteristics increases exponentially.
Statistical learning techniques using multivariate meth-
ods, such as dimension reduction and cluster analysis,
have the potential to assist in analyses of these compli-
cated problems. Our study demonstrates that application
of these techniques, even in a highly selected group of
subjects with severe emphysema, has the potential to
elucidate phenotypic heterogeneity and disease
pathophysiology.
Additional file 1: Supplementary Information. Supplemental Methods,
Results, and Figures.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1465-9921-11-
30-S1.DOC]
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